ESLA
Estrella Immunopharma, Inc.Company Information
- Company Name
- Estrella Immunopharma, Inc.
- CIK
- CIK0001844417
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ESLA: Nasdaq, ESLAW: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ESLA
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-10-07
- Last sale
- —
- Shares purchased (TTM)
- 1,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 4,794,274
- Shares outstanding
- 42,997,733
- Ownership
- 11.15%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -10.90%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
| Related Party | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0 | 4 | 0 | 0 | ||||||
| Cash And Cash Equivalents At Carrying Value | 0 | 2 | 1 | 2 | 1 | 0 | 2 | 4 | 5 | 9 | 22 | ||||||
Assets Current | |||||||||||||||||
| Assets Current | 2 | 2 | 2 | 2 | 1 | 1 | 2 | 4 | 9 | 9 | 27 | ||||||
| Prepaid Expense And Other Assets Current | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Held In Trust | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
Assets Noncurrent | |||||||||||||||||
| Prepaid Expense And Other Assets Noncurrent | - | - | 2 | - | - | - | 2 | - | - | - | - | ||||||
| Prepaid Expense Noncurrent | - | 2 | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 2 | 4 | 3 | 4 | 3 | 2 | 4 | 4 | 9 | 9 | 27 | ||||||
| Other Accounts Payable And Accrued Liabilities | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Sales And Excise Tax Payable Current | - | - | - | - | - | - | - | - | - | - | 5 | ||||||
| Other Notes Payable Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
Liabilities Current | |||||||||||||||||
| Accounts Payable And Other Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Liabilities Current | 9 | 9 | 14 | 13 | 9 | 4 | 3 | 0 | 0 | 0 | 17 | ||||||
| Accrued Liabilities Current | - | - | - | - | - | - | - | - | 0 | - | - | ||||||
| Taxes Payable Current | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Derivative Liabilities Current | 1 | 0 | 0 | 0 | 0 | - | - | - | - | - | - | ||||||
| Liabilities | 9 | 9 | 14 | 13 | 9 | 4 | 3 | 0 | 0 | 0 | 17 | ||||||
Stockholders Equity | |||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Stockholders Equity | -7 | -5 | -10 | -10 | -6 | -2 | 1 | 4 | 8 | 9 | 10 | ||||||
| Additional Paid In Capital | 35 | 35 | 27 | 27 | 26 | 25 | 24 | - | 24 | 24 | 24 | ||||||
Temporary Equity | |||||||||||||||||
| Retained Earnings Accumulated Deficit | -42 | -39 | -37 | -36 | -32 | -26 | -23 | -20 | -16 | -15 | -14 | ||||||
| Treasury Stock Value | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -0 | - | - | ||||||
| Additional Paid In Capital Common Stock | - | - | - | - | - | - | - | 24 | - | - | - | ||||||
| Liabilities And Stockholders Equity | 2 | 4 | 3 | 4 | 3 | 2 | 4 | 4 | 9 | 9 | 27 | ||||||
| Series A Preferred Stock | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | ||||||
| Series A A Preferred Stock | - | - | - | 0 | -0 | 0 | 0 | 0 | 0 | -25 | 0 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 44 | 43 | 38 | 38 | 38 | 37 | 37 | 37 | 37 | 35 | 35 | ||||||
| Shares Outstanding | - | - | - | - | - | - | - | 37 | 37 | 35 | 35 | ||||||
| Treasury Stock Common Shares | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEstrella Immunopharma, Inc. (ESLA) — SEC Financial Statements & Analysis
Estrella Immunopharma, Inc. (ESLA) is a biological products, (no diagnostic substances) company. Estrella Immunopharma, Inc. trades on Nasdaq as: ESLA, ESLAW. Estrella Immunopharma, Inc. (ESLA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Estrella Immunopharma, Inc. carries a market cap of $44.72M, a P/E ratio of -4.47x, a P/B ratio of -6.02x, an enterprise value of $44.57M, and an EV/EBITDA multiple of -4.55x. On profitability, it posts a Return on Equity (ROE) of 148.05% and a Return on Assets (ROA) of -416.74%. Per share, it reports EPS of $-0.23, diluted EPS of $-0.23, free cash flow per share of $-0.22, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -30.91% year-over-year and EPS growth of -41.88% year-over-year. On the balance sheet, it maintains a current ratio of 0.20x, a quick ratio of 0.18x, working capital of $-7.43M, a debt-to-equity ratio of -1.25x, a debt ratio of 5.07, free cash flow of $-9.38M (TTM), and net debt of $-146.67K. Figures sourced from SEC EDGAR.
- Market Cap
- $44.72M
- P/E TTM
- -4.47x
- EPS TTM
- $-0.23
- P/B TTM
- -6.02x
- ROE TTM
- 148.05%
- ROA TTM
- -416.74%
- Debt To Equity
- -1.25x
- Free Cash Flow TTM
- $-9.38M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Estrella Immunopharma, Inc. in?
Estrella Immunopharma, Inc. (ESLA) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ESLA trade on?
Estrella Immunopharma, Inc. (ESLA) trades on the Nasdaq.
When was Estrella Immunopharma, Inc. (ESLA)'s most recent SEC filing?
Estrella Immunopharma, Inc. (ESLA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is ESLA's market cap?
Estrella Immunopharma, Inc. (ESLA) has a market capitalization of $44.72M as of 2026-06-30.
What is ESLA's EPS (earnings per share)?
Estrella Immunopharma, Inc. (ESLA)'s trailing twelve month EPS is $-0.23 as of 2026-06-30.
What is ESLA's ROE (return on equity)?
Estrella Immunopharma, Inc. (ESLA)'s trailing twelve month Return on Equity (ROE) is 148.05% as of 2026-06-30.
What is ESLA's ROA (return on assets)?
Estrella Immunopharma, Inc. (ESLA)'s trailing twelve month Return on Assets (ROA) is -416.74% as of 2026-06-30.
What is ESLA's EV/EBITDA?
Estrella Immunopharma, Inc. (ESLA)'s trailing twelve month EV/EBITDA is -4.55x as of 2026-06-30.